For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
You are here : Home > PAD Profile : Latanoprost - Glaucoma / ocular hypertension
PAD Profile : Latanoprost - Glaucoma / ocular hypertension Important
Traffic Light Status
Status 1 of 1.
Guidelines
No guidelines returned.
Other Drugs
- Bimatoprost
- Timolol
- Dorzolamide and timolol
- Brinzolamide
- Brimonidine tartrate
- Dorzolamide
- Latanoprost and timolol
- Acetazolamide
- Timolol and bimatoprost
- Timolol and brimonidine
- Brinzolamide/brimonidine
- Brinzolamide and timolol
- Tafluprost
- Travoprost
- Timolol and travoprost
- Pilocarpine hydrochloride
- Betaxolol
- Levobunolol hydrochloride
- Apraclonidine
Other Indications
No indications returned.
Additional Documents
Committee Recommendations
Primary care prescribers do not have the necessary equipment or skills to perform ocular pressure readings to make a diagnosis. The APC recomments that this product, when used for treatment of glaucoma, should be considered as BLUE.
Note; the branded product (Xalatan) was considered as BLACK at the PCN in May 2017.
Pending the imminent patent expiry of Xalatan, generic latanoprost will be the most cost effective prostaglandin analogue in primary and secondary care. Acute trust colleagues are requested to initiate patients on generic latanoprost as the first line prostaglandin analogue. Xalatan prescribing in primary care should be changed to generic.